Pirsl F, Keruly J, Moore R, Lau B, Joshu C
Prev Med. 2024; 184:108000.
PMID: 38735585
PMC: 11168583.
DOI: 10.1016/j.ypmed.2024.108000.
Ruan X, Zhang N, Wang D, Huang J, Huang J, Huang D
JMIR Public Health Surveill. 2024; 10():e47161.
PMID: 38236627
PMC: 10835592.
DOI: 10.2196/47161.
Burgess L, Aldrighetti C, Ghosh A, Niemierko A, Chino F, Huynh M
JAMA Netw Open. 2022; 5(5):e2211869.
PMID: 35576008
PMC: 9112070.
DOI: 10.1001/jamanetworkopen.2022.11869.
Richards T, Dai S, Gray S, Hall I, Siegel D
Urol Oncol. 2022; 40(5):192.e19-192.e25.
PMID: 35236620
PMC: 9081142.
DOI: 10.1016/j.urolonc.2022.01.016.
Ravindranathan D, Alhalabi O, Rafei H, Shah A, Bilen M
Adv Exp Med Biol. 2022; 1342:143-192.
PMID: 34972965
PMC: 11235092.
DOI: 10.1007/978-3-030-79308-1_5.
Contributions of Social Factors to Disparities in Prostate Cancer Risk Profiles among Black Men and Non-Hispanic White Men with Prostate Cancer in California.
Press D, Shariff-Marco S, Lichtensztajn D, Lauderdale D, Murphy A, Inamdar P
Cancer Epidemiol Biomarkers Prev. 2021; 31(2):404-412.
PMID: 34853020
PMC: 8825684.
DOI: 10.1158/1055-9965.EPI-21-0697.
Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019.
Zi H, He S, Leng X, Xu X, Huang Q, Weng H
Mil Med Res. 2021; 8(1):60.
PMID: 34819142
PMC: 8611255.
DOI: 10.1186/s40779-021-00354-z.
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.
Islami F, Ward E, Sung H, Cronin K, Tangka F, Sherman R
J Natl Cancer Inst. 2021; 113(12):1648-1669.
PMID: 34240195
PMC: 8634503.
DOI: 10.1093/jnci/djab131.
Multilevel Small Area Estimation of Prostate-Specific Antigen Screening Test in the United States by Age Group: 2018 Behavioral Risk Factor Surveillance System.
Berkowitz Z, Zhang X, Richards T, Sabatino S, Peipins L, Smith J
J Am Board Fam Med. 2021; 34(3):634-647.
PMID: 34088823
PMC: 11154689.
DOI: 10.3122/jabfm.2021.03.200505.
Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.
Shahangian S, Sharma K, Fan L, Siegel D
Cancer Rep (Hoboken). 2021; 4(4):e1365.
PMID: 33934557
PMC: 8388177.
DOI: 10.1002/cnr2.1365.
Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.
Shahangian S, Fan L, Sharma K, Siegel D
Cancer Rep (Hoboken). 2021; 4(4):e1352.
PMID: 33932150
PMC: 8388175.
DOI: 10.1002/cnr2.1352.
Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017.
Clift A, Coupland C, Hippisley-Cox J
Br J Gen Pract. 2021; 71(703):e157-e165.
PMID: 33431381
PMC: 7805413.
DOI: 10.3399/bjgp20X713957.
The Association of Veterans' PSA Screening Rates With Changes in USPSTF Recommendations.
Becker D, Rude T, Walter D, Wang C, Loeb S, Li H
J Natl Cancer Inst. 2020; 113(5):626-631.
PMID: 32797212
PMC: 8096364.
DOI: 10.1093/jnci/djaa120.
ARHGEF38 as a novel biomarker to predict aggressive prostate cancer.
Liu K, Wang A, Ran L, Zhang W, Jing S, Wang Y
Genes Dis. 2020; 7(2):217-224.
PMID: 32215291
PMC: 7083745.
DOI: 10.1016/j.gendis.2019.03.004.
Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening.
Yang D, Makarov D, Gross C, Yu J
Cancer Control. 2020; 27(1):1073274820902267.
PMID: 32003227
PMC: 7003204.
DOI: 10.1177/1073274820902267.
Recent Patterns in Shared Decision Making for Prostate-Specific Antigen Testing in the United States.
Fedewa S, Gansler T, Smith R, Sauer A, Wender R, Brawley O
Ann Fam Med. 2018; 16(2):139-144.
PMID: 29531105
PMC: 5847352.
DOI: 10.1370/afm.2200.
Patterns of Prostate-Specific Antigen Test Use in the U.S., 2005-2015.
Berkowitz Z, Li J, Richards T, Marcus P
Am J Prev Med. 2017; 53(6):909-913.
PMID: 29051016
PMC: 6077842.
DOI: 10.1016/j.amepre.2017.08.003.
